Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best performing ...
Bryan Johnson, the American entrepreneur renowned for his anti-ageing endeavours, has disclosed the details of his latest ...
The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Johnson & Johnson is well-diversified across thriving healthcare segments, with promising FDA approvals. Read why I assign a ...
Many Indians laid low by disease have turned to biohacking. Others are healthy but want to live longer. Aiding them in their ...
Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity ... That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March ...
The ARTfactory in Manassas will present the critically acclaimed one-man play, “Every Brilliant Thing” from Feb. 28 through March 2.
To a degree possibly unprecedented in the country’s nearly 250 years, President Trump is barreling through the executive ...